For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”

Tara L. Lin, MD, shares the initial findings from a trial evaluating venetoclax with standard low-dose cytarabine in older patients with acute myeloid leukemia who are unfit for intensive chemotherapy.

SHARE